The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
falcarinol results in decreased expression of and results in decreased activity of CASP3 protein falcarinol results in decreased expression of CASP3 protein modified form
falcarinol inhibits the reaction [PDGFB protein results in increased phosphorylation of CREB1 protein]; falcarinol inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; falcarinol inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK3 protein]
[perifosine co-treated with Butyrates] results in increased secretion of AIFM1 protein; [perifosine co-treated with trichostatin A] results in increased secretion of AIFM1 protein; [perifosine co-treated with vorinostat] results in increased secretion of AIFM1 protein
[perifosine co-treated with Butyrates] results in decreased activity of AKT1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of AKT1 protein; [perifosine co-treated with Vorinostat] results in decreased activity of AKT1 protein; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Butyrates]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with trichostatin A]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Vorinostat]; perifosine inhibits the reaction [cyadox results in increased phosphorylation of AKT1 protein] perifosine results in decreased phosphorylation of AKT1 protein [perifosine co-treated with temsirolimus] results in decreased activity of AKT1 protein
[perifosine co-treated with Butyrates] results in decreased expression of BAK1 protein; [perifosine co-treated with trichostatin A] results in decreased expression of BAK1 protein; [perifosine co-treated with vorinostat] results in decreased expression of BAK1 protein
[perifosine co-treated with Butyrates] results in increased activity of BAX protein; [perifosine co-treated with trichostatin A] results in increased activity of BAX protein; [perifosine co-treated with vorinostat] results in increased activity of BAX protein
[perifosine co-treated with Butyrates] results in increased activity of CASP3 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP3 protein; [perifosine co-treated with vorinostat] results in increased activity of CASP3 protein perifosine results in decreased expression of CASP3 protein
[perifosine co-treated with Butyrates] results in increased activity of CASP8 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP8 protein; [perifosine co-treated with vorinostat] results in increased activity of CASP8 protein
[perifosine co-treated with Butyrates] affects the localization of CYCS protein; [perifosine co-treated with trichostatin A] affects the localization of CYCS protein; [perifosine co-treated with vorinostat] affects the localization of CYCS protein
perifosine inhibits the reaction [cyadox results in increased expression of EGF]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of EGF]
[perifosine co-treated with cyadox] results in increased expression of FOXO1 mRNA; [perifosine co-treated with Hydrogen Peroxide] results in increased expression of FOXO1 mRNA perifosine inhibits the reaction [cyanoginosin LR results in increased phosphorylation of FOXO1 protein]
ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein] LAT2 protein results in decreased susceptibility to perifosine
MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with Butyrates]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat]
[perifosine co-treated with Butyrates] results in decreased activity of MAPK1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK1 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK1 protein
[perifosine co-treated with Butyrates] results in decreased activity of MAPK3 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK3 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK3 protein
[perifosine co-treated with Butyrates] results in increased activity of MAPK8 protein; [perifosine co-treated with trichostatin A] results in increased activity of MAPK8 protein; [perifosine co-treated with vorinostat] results in increased activity of MAPK8 protein
perifosine inhibits the reaction [cyadox results in increased expression of TP53 mRNA]; perifosine inhibits the reaction [cyadox results in increased expression of TP53 protein]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA]
Phytol results in increased expression of ALDH3A2 protein PPARA protein affects the reaction [Phytol results in increased expression of ALDH3A2 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK1 protein]]; Acetylcysteine affects the reaction [Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK1 protein]]; Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK3 protein]]; Acetylcysteine affects the reaction [Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK3 protein]]; Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] which results in decreased ubiquitination of MITF protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]]; [Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] which results in decreased ubiquitination of MITF protein; Acetylcysteine inhibits the reaction [Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] which results in decreased ubiquitination of MITF protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]]; Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytol inhibits the reaction [alpha-MSH results in increased expression of TYR protein]]; Phytol inhibits the reaction [alpha-MSH results in increased expression of TYR protein]
browse the term
